Published in Blood Weekly, October 31st, 2002
The trial was conducted at the Karolinska Institute in Stockholm, Sweden in April and May 2002 and involved healthy volunteer subjects. No adverse events attributable to Hemospan were noted during the trial.
Hemospan represents a new approach in oxygen transport technology and is distinct from blood substitute products that have languished in decades-old clinical research. Sangart's products are chemically modified hemoglobin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.